V-Go® Data and Clinical Benefit Discussed During Panel Presentation on Insulin Therapy and Delivery at AADE 2016

BRIDGEWATER, N.J., Aug. 15, 2016 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (OTCQB:VLRX) announced today that clinical data demonstrating the clinical benefits of V-Go, the Company’s disposable insulin delivery device designed with the needs of the patient with Type 2 diabetes in mind, were highlighted in a presentation at the American Academy of Diabetes Educators (AADE) annual meeting at the San Diego Convention Center in San Diego, CA. In addition, demonstrations to clinicians on V-Go’s ease of use were available from Aug. 12 to 14 at the Company’s booth, #437, in the Exhibition Hall at the convention center.

A multi-clinician oral presentation outlining insulin therapy and delivery highlighted V-Go as one of the recent advances in insulin delivery. The presentation cited strong V-Go clinical data for patients previously not achieving their therapeutic goals with basal insulin delivered via a syringe or insulin pen. Patients initiated on V-Go for basal-bolus insulin delivery experienced significantly greater glycemic improvement from baseline compared to patients receiving basal-bolus therapy via multiple daily injections of insulin. By 12 weeks, A1C least squares mean change from baseline was −1.82% with V-Go and -0.98% with multiple daily injections. Results favored V-Go for both the 12-week and 27-week analysis, and V-Go was found to be a more cost-effective method for basal-bolus insulin delivery compared to multiple daily injections.

John Timberlake, President and Chief Executive Officer of Valeritas said, “The advancements in the delivery of insulin offered with V-Go allow discreet insulin delivery, convenient dosing and simplicity that assists with efficacy and compliance. V-Go offers a novel way to deliver insulin and has been well received by patients as a result of addressing many of the barriers patients face when basal-bolus therapy is necessary.”

About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on developing innovative technologies to improve the health and quality of life of people with Type 2 diabetes. Valeritas' flagship product, the V-Go® Disposable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate infusion of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery system on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in a state-of-the-art facility in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.

Forward Looking Statements:
This press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Disposable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.

Investor Contact: Nick Laudico / Zack Kubow The Ruth Group (646)536-7030 / 7020 IR@valeritas.com Media Contact: Christopher Hippolyte The Ruth Group (646)536-7023 PR@valeritas.com

Source:Valeritas, Inc.